Aliya Jaber

ORCID: 0009-0007-4513-0895
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Fibroblast Growth Factor Research
  • SARS-CoV-2 and COVID-19 Research
  • Hippo pathway signaling and YAP/TAZ
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Nanoplatforms for cancer theranostics
  • Vaccine Coverage and Hesitancy
  • Kruppel-like factors research
  • Chromatin Remodeling and Cancer
  • Antimicrobial agents and applications
  • Multiple Sclerosis Research Studies
  • Immunotherapy and Immune Responses
  • Polyomavirus and related diseases

Saint Barnabas Medical Center
2023

Dana-Farber Cancer Institute
2020-2021

Harvard University
2021

Simmons University
2019

Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune in people with MS (PwMS) receiving different DMTs. This prospective, open-label observational study enrolled 45 participants treated natalizumab (n = 12), ocrelizumab 16), fumarates (dimethyl fumarate or diroximel fumarate, n 11), interferon beta 6); ages 18–65 years inclusive; stable on DMT for at least 6 months. Responder rates,...

10.1007/s40120-023-00448-x article EN cc-by-nc Neurology and Therapy 2023-02-16

Vaccines against the SARS-CoV-2 virus were authorized for use by Food and Drug Administration (FDA) in United States have proven effective prevention of morbidity death from COVID-19. Certain immunosuppressant medications prevent development protective immunity following COVID-19 vaccination. In December 2021, FDA issued an emergency authorization (EUA) a monoclonal-antibody combination tixagevimab cilgavimab, under brand name Evusheld, pre-exposure prophylaxis (PrEP) individuals with...

10.3390/vaccines11121855 article EN cc-by Vaccines 2023-12-15

Abstract How cancer cells adapt to evade the therapeutic effects of drugs targeting oncogenic drivers is poorly understood. Here we report an epigenetic mechanism leading adaptive resistance triple-negative breast (TNBC) fibroblast growth factor receptor (FGFR) inhibitors. Prolonged FGFR inhibition suppresses function BRG1-dependent chromatin remodeling state that derepresses YAP-associated enhancers. These changes induce expression several amino acid transporters resulting in increased...

10.1101/2021.03.02.433446 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2021-03-02

Due to the prevalence of nosocomial infections, need for enhanced precaution between health care provider and patient has increased. In attempt eliminate scrubs as a transmission vector, this project focused on methodology behind integrity known antibacterial terpolymers scrub fabric. Terpolymer function immobilization, water solubility, activity was tested through manipulation ratios 1‐(4‐vinylbenzyl) thymine (VBT), vinylbenzyl trimethyl QUAT (TMQ), dimethylhexadecyl (DMHDQ), respectively....

10.1096/fasebj.2019.33.1_supplement.471.2 article EN The FASEB Journal 2019-04-01

Abstract Brain metastases (BM) are a leading cause of cancer death and prognosis remains poor despite treatment advances at other sites. Models central to therapeutic development, but few orthotopic patient-derived xenograft (PDX) models BM exist. To represent diversity across types, we established program create PDX scale from all patients. date were received 100 patients attempted by direct brain injection (PDX, n=89) or low passage cell lines (PDCLX, n=11). We created 65 successful 13...

10.1093/noajnl/vdaa073.034 article EN cc-by-nc Neuro-Oncology Advances 2020-08-01

Abstract Brain metastases (BM) are a leading cause of cancer death and prognosis remains poor despite treatment advances at other sites. Models central to therapeutic development, but few orthotopic patient-derived xenograft (PDX) models BM exist. To represent diversity across types, we established program create PDX scale from all patients. date were received 100 patients attempted by direct brain injection (PDX, n=89) or low passage cell lines (PDCLX, n=11). We created 65 successful 13...

10.1093/neuonc/noaa215.954 article EN Neuro-Oncology 2020-11-01
Coming Soon ...